The Role of the Mutant p53-PARP-MCM Pathway in Triple Negative Breast Cancer

This research, presented as a comprehensive proteomic and functional analysis of gain-of-function mutant p53 (mtp53) in triple negative breast cancer (TNBC), defines and validates a chromatin-associated functional axis linking mtp53, poly ADP-ribose polymerase (PARP), and the minichromosome maintenance (MCM) complex (MCM2-7). Recognizing that over 80% of TNBC tumors express mtp53, the investigators used inducible knockdown of endogenous R273H mtp53 in MDA-MB-468 cells combined with stable isotope labeling by amino acids in cell culture and subcellular fractionation to map the mtp53-associated proteome. Sequencing of tens of thousands of peptides enabled identification of thousands of unique proteins in both cytoplasmic and chromatin fractions, corroborating prior observations that PARP positively associates with mtp53 on chromatin and, for the first time, highlighting the heterohexameric MCM complex central to DNA replication initiation as a high-ranking mtp53-chromatin-associated pathway. Enrichment analyses specifically identified MCM members 2-7.

Functional validation showed that depletion of R273H mtp53 substantially reduced the chromatin-bound levels of MCM proteins, and direct protein-protein interactions were detected between mtp53 and MCM2. Overexpressed mtp53, but not wild-type p53, interacted with MCM2 and MCM4, indicating a gain-of-function mechanism that links mtp53 to replication licensing machinery. To explore therapeutic implications, the team treated mtp53-expressing cells with the PARP inhibitor talazoparib and the alkylating agent temozolomide. The combination produced synergistic activation of apoptosis selectively in the presence of mtp53, suggesting a context-dependent vulnerability. Crucially, inhibition of MCM-7 activity blocked this synergistic apoptosis, demonstrating that active MCM function is required for the observed drug synergy and supporting a mechanistic model in which mtp53 regulation of MCM activity and PARP association underlies sensitivity to combined PARP inhibitor and DNA-damaging therapy.

These findings propose the mtp53-PARP-MCM axis as both a potential biomarker and therapeutic target in TNBC, with implications for theranostics and personalized medicine: tumors harboring mtp53 may be preferentially susceptible to specific drug combinations that exploit their altered chromatin and replication-associated protein interactions. The work emphasizes the importance of proteome-level analyses in uncovering nontranscriptional chromatin functions of mtp53, complements transcriptomic studies, and advances understanding of how mtp53 reprograms chromatin and replication-associated pathways to promote oncogenic phenotypes. Overall, the study identifies a novel mtp53-associated chromatin axis, validates direct interactions and functional dependence, and demonstrates a druggable vulnerability that is contingent on both mtp53 presence and active MCM complex function, laying groundwork for future preclinical and translational studies to refine patient selection and therapeutic strategy in mtp53-positive TNBC.